Biopharma in 2008: What a Difference an Economic Crisis Makes
Executive Summary
Even before the financial meltdown, 2008 was a remodeling year for the biopharmaceutical world. Many pharma companies, more reliant on the product candidates and technologies of the biotech world than ever, were pinned down by excess infrastructure and lagging productivity. But when the world's cash dried up, so, too, did biotech's leverage over those downtrodden in-licensers and acquirers. We highlight some top trends from a difficult year that may shape industry in 2009 and beyond.
You may also be interested in...
Biopharma Trends: Nowhere To Go But Up
Biopharmaceutical trends in 2008 were fundamentally altered by the global financial crisis. And 2009's events were similarly impacted by the ongoing recovery. VCs hunkered down as capital and exits remained scarce, and pharmaceutical acquirers remained cautious.Those deals that did get done were typically structured affairs or options-to-deal. In addition, health care reform added to the ongoing drama and uncertainty
Biopharma Trends: Nowhere To Go But Up
Biopharmaceutical trends in 2008 were fundamentally altered by the global financial crisis. And 2009's events were similarly impacted by the ongoing recovery. VCs hunkered down as capital and exits remained scarce, and pharmaceutical acquirers remained cautious.Those deals that did get done were typically structured affairs or options-to-deal. In addition, health care reform added to the ongoing drama and uncertainty
2008's Top Biopharma Dealmakers
Last year was dominated by the weakening financial markets and cash-strapped biotechs trying to find alternative sources of capital. But 2008 still managed to produce uniquely structured biopharma partnerships and groundbreaking takeovers that moved acquirers into new businesses. Below we focus below on the dealmakers, showing which companies dominated the dealmaking landscape in terms of volume, as well as the therapeutic areas that grabbed the most attention.